Aceragen, Inc. Banner Image

Aceragen, Inc.

  • Ticker ACGN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aceragen, Inc. Logo Image
  • 51-200 Employees
  • Based in Exton, Pennsylvania
Aceragen is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Their lead product candidate, ACG-701, is an oral, loading dose formulation of sodium fusidate that is in development for the treatment of melioidosis and acute pulmonary exacerbations associated with cystic fibrosis. ACG-701 has receivedMore Fast Track Designation, Orphan Drug Designation, and Qualified Infectious Disease Product (QIDP) from the FDA in acute exacerbations with cystic fibrosis. Aceragen is also developing ACG-801, recombinant human acid ceramidase, as an enzyme replacement therapy for an untreated lysosomal storage disorder called Farber disease.
4.8 / 5.0 (142)

Aceragen, Inc. reports have an aggregate usefulness score of 4.8 based on 142 reviews.

Aceragen, Inc.

Most Recent Annual Report

Aceragen, Inc.
MOST RECENT 2022 Annual Report

Aceragen, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Aceragen, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!